mercredi 26 septembre 2018

Onco Actu du 26 septembre 2018


1. Biologie

Most tumors in body share important mutations [NIH]

2. Etiologie

Transplant-linked cancer deaths pose questions about safety [UW Medicine]

3.1.1 Prévention - Tabac - e-cigs

Imperial to launch new e-cigarette alongside heated tobacco [Reuters]

FDA is considering banning online sales of e-cigarettes: Gottlieb [Reuters]

4.1 Dép., diag. & prono. - Prostate

More doctors say men should think twice about prostate cancer screening [Reuters]

4.2 Dép., diag. & prono. - Génome

NIH-funded genome centers to accelerate precision medicine discoveries [NIH]

5. Traitements

5 Recent Advancements in Pediatric Cancer Treatment [Dana-Farber Cancer Institute]

5.1 Traitements - Pré-clinique

New drug candidate makes cancer cells more sensitive to radiotherapy [Karolinska Institutet]

New Drug Blocks Pancreatic Cancer Growth in Mice, Study Finds [Cedars-Sinai]

5.12 Immunothérapies

Smuggling RNA into cells can activate the immune system to fight cancer [Stanford Medicine]

5.12.5 Immunothérapies - Pharma

Transgene unveils myvacTM , an individualized immunotherapy against solid tumors [Transgene]

5.12.8 Immunothérapies - Economie

NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE's decision making process [Pharmafile]

5.13.1 WCLC - Immunothérapies

Roche’s IMpower133 offers a glimpse at rare progress in fight against small cell lung cancer [EndPoints]

Roche eyes $1B-plus Tecentriq nod with small-cell lung cancer survival win [FiercePharma]

Roche’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer [Roche]

AstraZeneca spells out a major drop in the risk of death for stage 3 NSCLC patients taking Imfinzi — and why that’s important [EndPoints]

Atezolizumab Improves Outcomes for Small Cell Lung Cancer When Added to Standard-of-Care Treatment [IASLC]

AstraZeneca immunotherapy drug cuts lung cancer deaths by almost a third [Reuters]

PACIFIC Study Shows Durvalumab Improves Overall Survival in Patients with Unresectable Non-Small Cell Lung Cancer Without Progression after Chemoradiotherapy [IASLC]

5.13.2 WCLC - Thérapies ciblées

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC [Takeda]

LUME-Meso Study Shows Nintedanib Plus Pemetrexed/Cisplatin Does Not Improve Progression-Free or Overall Survival in Patients With Malignant Pleural Mesothelioma of Epithelioid Subtype [IASLC]

Interim Analysis of ALTA-1L Demonstrates Potential for Brigatinib as First-Line Treatment Option for ALK-Positive Non-Small Cell Lung Cancer [IASLC]

5.13.3 WCLC - Dépistage

Trial Results Show Screening Significantly Reduces Lung Cancer Mortality Rates [Lung Cancer Alliance]

NELSON Study Shows CT Screening for Nodule Volume Management Reduces Lung Cancer Mortality by 26 Percent in Men [IASLC]

5.2.3 Pharma - économie

TG stock sinks after setback to blood cancer trial [FierceBiotech]

5.3.4 Traitements - AMM (FDA, EMA,...)

EMA Recommends Extension of Therapeutic Indications for Enzalutamide [ESMO]

6.12 Ethique

One top oncologist failed to disclose payments from big pharma. That hurts all cancer patients [The Guardian]

Cancer Center Switches Focus on Fund-Raising as Problems Mount [NY Times]

6.6 Publications

Next Steps for ORCID and Organization Identifiers [ORCID]

No more first authors, no more last authors [Nature]

6.7.3 DMP

Paper Trails: Living and Dying With Fragmented Medical Records [Undark]